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InterventionaliWswere energizedin 1994by the reports of
randomizedtrialscomparingstentswith balloonangioplasty
percutaneoustransluminalcoronaryangioplasty(PTCA)for
the treatment of coronaryartery disease (1,2). The initial
promisethat stentingmightreducerestenosiswasconvincingly
demonstratedin the StentRestenosisStudy(STRESS)I and
BelgianNetherlandsStent(BENESTENT)I trials.Anapprox-
imate 30’%reductionin late restenosiswith the use of the
Palmaz-Schatzstentin additionto a significantdecreasein the
needfor repeatrevascularizationwasseen.Althoughresteno-
siswas decreased,hospitalstayand bleedingwere increased
with stentingbecauseof the perceivednecessityfor heparin
and Coumadin therapy after stent deployment.Recent
changesinthe anticoagulationregimenwiththesubstitutionof
ticlopidinefor post-stentheparin and Coumadinhave de-
creasedbothhospitalstayandbleedingaswellasthe incidence
ofsubacutethrombosis(3,4).Thelong-termsafetyandefficaey
of stentinghave also been questioned(5). However,in this
issue of the Journal,Laham et al. (6) report an excellent
long-termoutcome(4 to 6 years) for patients undergoing
electivePalmaz-Schatzstenting,particularlyinnativecoronary
arteries(6).
Currentpractices in interventionalcardiology.Based in
partonthepreviousdata,stentsarenowbeingusedextensively
as the primarytherapyfor coronaryartery lesions.In many
laboratories,nonballoontechnologyisusedin >50%ofcases,
and stents represent the most frequentlyused new device.
Combinationsof devices(e.g.,Rotablatorand stentor direc-
tionalatherectomyand stents)have also beingreportedre-
cently(7,8).As an indicationof thepopularityof stents,at the
recentAmericanCollegeof Cardiologymeetingin Orlando,
there were 104 abstractspresentedon coronarystents-15
more than presentedon the entire subjectof heart failure.
Thus,“stentmania”appearsto be a real condition.













Administration-approvedstentingis the rule rather than the
exception.The use of multiplestentsor stentingin restenotic
lesionsor saphenousvein grafts was commonplace,even
before the resultsof randomizedtrials indicatedthat such
therapymightreducerestenosis.This therapyis indeedvery
expensive.In the STRESStrial, the averagecatheterization
laborato~costsforstentswere$1,200.00morethanforPTCA,
and in-hospitalcostswere
-$2,200.00more per patient (9).
The use of multiplestents at a cost of -$l,500.00/stent,
followedby a highpressureballoonand intravascularultra-
sound,addsexponentiallyto the costof the procedurecom-
pared with that for primary PTCA. These costs must be
absorbedbythe hospitalbecausethesenewer,moreexpensive
devicesare not reimbursable.Anotherpotentialproblemwith
stentsis the optimaltherapyfor stentrestenosis.
Alternativesolutions. Is there an alternativethat doesnot
subjectpatients to increasedrisk or decreasedefficaey?If
“stentmania”is a malady,is therea cure?In manylesions(at
least typesA and B AmericanHeart Association/American
Collegeof Cardiologyclassification),PTCAhas a highinitial
successrate and in 50’%0to 7070of casesis unassociatedwith
laterestenosisor theneedforrepeatintervention.If onecould
identifythose lesionswith long-termsuccess,the need for
other deviceswoulddiminish.Analysisof the resultsof the
STRESSand BENESTENTtrialsin conjunctionwithrecent
workon earlylossin lumendiameterafterPTCAmayprovide
an answer(10,11).In both the STRESSand BENESTENT
trials(Table1), the meanminimallumendiameter(MLD)at
late follow-upwasonlybetween0.10and0.18mmlarger(net
gain)for stentsversusPTCA.In both trials, the immediate
gain was significantlygreater for stents than for balloons
(BENESTENT:1.40vs.0.97mm,STRESS:1.72vs.1.23mm,
respectively).In addition,the late losswas also greater for
stents than for PTCA (BENESTENT:0.65 vs. 0.32 mm,
STRESS:0.74vs.0.43mm,respectively).Thenet gain(imme-
diategainminuslateloss)for stentswasthereforequitesmall,
Onemightarguethat the techniquesfor deploymentof stents
used in the STRESSand BENESTENTtrialsare nowobso-
lete.However,in BENESTENTII therewasonlya smallbut
significantdecreasein the postproceduralpercent diameter
stenosisin the stent group,utilizingthese newertechniques
(21%~ 7% in BENESTENTI vs.18%t 6% BENESTENT
II) (12).
Fromanalysisof the tworandomizedtrials,the immediate
gainfor PTCAis lessthan that for stents.However,the late
loss for PTCA is also less than that for stents and other
techniquesuchaslaserandatherectomy(13).Notonlyis late
lossless,but serialangiogramsafterPTCAalsoindicatethat
the lossin minimallumendiameter(MLD)iscomposedof at
leasttwocomponents—anearlycomponentmanifestingitself
within24 h and a late componentoccurringduringthe 6- to
8-monthfollow-upvisit.Rodriguezet al. (10),in a consecutive
groupundergoingPTCA,performed24-hand 6- to 8-month
angiographymeasuringpercent diameterstenosisand MLD












(Table 2), the mean MLD in groups I and H after the
procedurewas2.59mmby core laboratoryquantitativecoro-
naryangiography.Again,combining roupsI andII, theMLD
at 24h (earlyloss)was2.49mm,and at later follow-upit was
2.14mm.EventhoughtheMLDsin thisstudywerelargerthan
that recordedin otherstudies,eachpatientwashisor her own
control.The total loss in MLD was therefore0.44mm for
combinedGroupsI and II (MLD2.59to 2.15mm),and the
averageearlylosswas0.10mm,or 23Y0(0.10/0.44mm)of the
entireloss.FromanalysisofTable2, 19lesions(groupII) had
an earlyloss,causinga >1OYOincreasein diameterstenosisat
24 h comparedwith that after PTCA,with a concomitant
decrease in lumen diameter (MLD 2.42 * 0.37 mm after
PTCAvs.2.01t 0.32mmat 24h),whereas71lesions(group
I) hadno earlyloss(2.63mmafterPTCAvs.2.62mmat 24h).
ThelatelossingroupI wasonly0.21mmat follow-up,whereas
that forgroupII was0.84mm,whichtranslatedto a restenosis
rate (utilizingthe 50%cutotf)of 7470forgroupII versusonly
10% for group I (p < 0.001).In a subsequentpublication,
lesionswith earlylossat 24 h were randomizedinto a stent
groupversusno additionalintervention(11).At late angio-
graphicfollow-up,restenosiswas2170in thestentgroupversus
70%for no additionalintewention(p < 0.001).Subsequently,
80%oflesionswithearlylossat24hwilldemonstratethesame
amountof earlyloss1 h after PTCA(14).
Thus, a delayedangiogramafter PTCA may identifya
groupinwhomearlylosspredictslaterestenosis.The absence
of early loss also predictsa low restenosisrate, and in the
presenceofearlylossa stentwillsignificantlyreducerestenosis









(n= 71) (n= 19) (n= 90)
MLDafterprocedure 2.63t 0.33 2.42? 0.37 2.59
(mm)
MLDat 24-h(early) 2.62t 0.3 2.01t 0.32 2.49
follow-up(mm)
MLDat latefollow-up 2.41f 0.56 1.17~ 0.64 2.15
(mm)
*ModitiedfromRodriguezet al. (10).MLD= minimalumendiameter.
tinelyperformedin patientswithunstableanginaundergoing
PTCA.These angiogramsidentifiedthrombusfour timesas
frequentlyin the 15-minangiogramasin the l-reinpost-PTCA
angiogramin additionto a meandecreasein MLDof 0.3mm
at 15min.
If we extendthese observationson early lossto the ran-
domizedtrials, the mean late loss in MLD with PTCA in
BENESTENTand STRESS(0.32to 0.43mm, respectively)
mayconsistof twocomponents—anearly(s24 h) lossand a
moredelayedloss.If earlylosscontributes-23Y0to the total
late loss(10),and if thiswassubtractedfromthe late lossin
MLDfor PTCA,the true late losswouldhavebeen 0.25and
0.33mm,respectively.The theoreticnet gain(excludingearly
loss) of stents would be decreased to only 0.03 mm in
BENESTENTand 0,08mm in STRESSinsteadof 0.10and
0.18mm, respectively(Table3). Becauseof the scaffolding
effectof stents,the late loss in MLD with stentsmay be a
modelforintimalproliferation,andotherfactorssuchasrecoil
andremodelingarelessimportantwithstentsthanwithPTCA.
Serruyset al. (18)recentlyreportedthat a stentlikeresult
with PTCA (s3070 diameterstenosis)couldbe achievedin
35% of patients in the BENESTENTI trial (18). Their
restenosisrate of 1690at follow-upis consistentwith the
observationthat an excellentinitialPTCA result has a low
incidenceof restenosis.Furthermore,from analysisof the
STRESSresults,there was no added benefitof stentsover
PTCAin reducingrestenosisin vessels>3.4 mmin diameter
(19).
Implicationsandconclusions. Dothesedataleadusto any
conclusions?We think it importantthat a multicenter,ran-
domizedtrial test the hypothesisthat early loss in lumen
Table1. AngiogmphicResults(mean~ SD)inBENESTENTI andSTRESSI Trials*
BENESTENT STRESS
STENT PTCA STENT PTCA
(n= 259) (n= 257) (n= 205) (n= 202)
MLDafterprocedure(mm) 2.48t 0.39 2.05t 0.33 2.49t 0.43 1.99t 0.47
Immediategain(mm) 1.40t 0.44 0.97i 0.39 1.72f 0.46 1.23* 0.48
Lateloss(mm) 0.65f 0.57 0.32f 0.47 0.74t 0.58 0.43t 0.66
Netgain(mm) 0.75t 0.66 0.65f 0.59 0.98~ 0.62 0.80t 0.63







Table 3. Differences in Net GainBetweenStentsandPercutaneous
TransluminalCoronaryAngioplasty
BENESTENT STRESS
Stent PTCA Stent PTCA
Immediategainminuslate 0.75 0.65 0.98 0.80
lossin MLD(mm)








diameterwithPTCAidentifiesa subgroupat risk for a high
restenosisrate.Asa corollaryto thishypothesis,a goodinitial
resultofPTCAwithoutrecoilshouldresultin a lowrestenosis
rate at 6 months.A trial comparingstentingwith optimal
PTCAshouldbeperformedwithdelayedangiographyto assess
earlylossandallowforcrossoverto stentingiftheinitialPTCA
is inadequateor if early loss occurs.Althoughthe optimal
timingof delayedangiographyis unknown,a delayedangio-
gramat 15to 30minwillprobablycapturemostcasesof early
loss,yet not greatlyinconveniencepatients,interventionists
and busylaboratories.Twoparallelpilot trialsare presently
ongoingin the UnitedStatesand Argentina,
Studiessimiliarto thesetwopilottrials,whetherpositiveor
negative,are important.Ifwecouldidentifythoselesionsthat
respondedfavorablyto PTCAand didnot requireadditional,
morecostlyinterventions,thecostsavingswouldbe enormous.
In contrast,if this and other PTCA strategiesfail, then the
currententhusiasmfor stentingis appropriateand doesnot
require a cure. Future studies of stentingwould thus be
directedat reducingrestenosisevenfurtherwhiledecreasing
cost.Untiltheseissuesare settled,it isreassuringthat the late
outcomeofstentingin treatedlesionsasreportedbyLahamet
al. appearsto be favorable.
References













FischmanDL, LeonMB,BairnD, et al. A randomizedcomparisonof
coronarystent placementand balloonangioplastyin the treatmentpf
coronaryarterydisease.N EnglJ Med1994;331:496-501.







TopolEJ. Caveatsabout electivecoronarystenting.NewEnglJ Med
1994;331:539-41.
LahamRJ, CarrozzaJP, BergerC, CohenDJ, KuntzRE, BairnDS.
Long-term(4-to 6-year)outcomeafterPalmaz-Schatzstenting:paucityof
late stent-relatedproblems.J AmCoilCardiol1996;28:820-6.












11.Rodriguez~, SantaeraO, LarribauM,et al. Coronarystentingdecreases
restenosisin lesionswith earlyloss in hnninaldiameter24 hoursafter
successfulPTCA.Circulation1995;91:1397-402.


















AmbroseJ~ AlmeidaOD,SharmaS,et al.,for theTAUSAInvestigators.
Adjunctivethrombolytictherapyduringangioplastyforischemicrestangina
resultsof theTAUSAtrial.Circulation1994;90:69-77,
MehranR, AmbroseJA, BongcrRM.Angioplastyof complexlesionsin
Ischemicrestangina:resultsofthethrombolysisandangioplastyinunstable
angina(TAUSA).J ArnCoilCardiol1995;26:961-6.
SerrnysPW,AzarAJ, SigwartU, et al., on behalfof the BENESTENT
group.Long-temrfollow-upof“stent-like”(=30%diameterstenosis)post-
angioplasty:a casefor provisionalstenting[abstract].J Am Co]]Cardiol
1996;27:15A.
AzarAJ, Detre ~ GoldbergS, KiemeneijF, LeonMB,SermysPW,on
behalfof theBenestentandStentRestenosisStudy.A meta-analysisonthe
clinicaland angiographicoutcomesof stentsvs PTCAin the different
coronaryvesselsizesin the BENESTENT-Iand STRESS-1/2trials [ab-
stract].Circulation1995;92Suppl1:1-475.
